Assessment of the effect of nanocurcumin supplement in patients with COVID-19

Not Applicable

Recruiting

• Conditions: COVID-19.; Coronavirus infection, unspecified; U07.1

• Registration Number: IRCT20131125015536N13
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 October 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

Confirmation of Covid-19 by positive PCR test or lung scan
Admission to hospital Corona wards other than ICU
Filling out the informed consent form by the patient or the patient's first-degree relatives

Exclusion Criteria

Chemotherapy
People living with HIV
History of heart attack and stroke in the last 3 months
History of CABG
Dialysis patients
Transplantation of body organs
Pregnancy and lactation
People with BMI above 40
Known food allergies
Having any liver failure
Malignancies
Uncontrolled Diabetes (A1c>7.5)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hs-CRP. Timepoint: Before and after 6 days of supplementation. Method of measurement: ELISA.;Percentage of recovery. Timepoint: Before and after 6 days of supplementation. Method of measurement: CT scan of the lungs.

Secondary Outcome Measures

Name	Time	Method
Percentage of oxygen saturation. Timepoint: Before the intervention and then daily until discharge. Method of measurement: Pulse oximeter.;Severity of infection symptoms of upper and lower respiratory tract. Timepoint: Before the intervention and then daily during the supplementation period. Method of measurement: Questionnaire.;Complete Blood Count. Timepoint: Before and after 6 days of supplementation. Method of measurement: Automated cell count.